[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100557673":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":12,"centralContacts":16,"locations":21,"responsibleParty":33,"collaborators":7,"id":35,"slug":7,"hasResults":36,"nctId":37,"briefTitle":38,"officialTitle":39,"acronym":40,"eligibilityCriteria":41,"healthyVolunteers":36,"sex":42,"minAge":43,"maxAge":7,"enrollmentInfo":44,"targetDuration":7,"studyType":47,"phases":7,"briefSummary":48,"conditions":49,"keywords":7,"overallStatus":52,"whyStopped":7,"lastUpdateSubmitDate":53,"lastUpdatePostDateStruct":54,"startDateStruct":57,"completionDateStruct":59,"leadSponsor":61,"locationsCount":62},{"fullName":5,"class":6},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","OTHER",null,[9],{"type":6,"name":10,"description":11,"armGroupLabels":7,"otherNames":7},"Magnetic resonance imaging as fpr clinical practice","An abbreviated MR protocol of the abdomen will be used inh association with CT scan; it does not need contrast injection and does not add any risk for patients.",[13],{"name":14,"affiliation":5,"role":15},"Giacomo Avesani","PRINCIPAL_INVESTIGATOR",[17],{"name":14,"role":18,"phone":19,"phoneExt":7,"email":20},"CONTACT","+390630156054","giacomo.avesani@policlinicogemelli.it",[22],{"facility":23,"status":7,"city":24,"state":7,"zip":25,"country":26,"cosmosGeoPoint":27,"geoPoint":32,"contacts":7},"Fondazione Policlinico Universitaro \"A. Gemelli\" IRCCS","Roma","00168","Italy",{"type":28,"coordinates":29},"Point",[30,31],11.10642,44.99364,{"lat":31,"lon":30},{"type":34,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100557673",false,"NCT06541171","A New Fast DWI-based MR Protocol for Surveillance in Patients With a High Risk of Ovarian Cancer Recurrence During PARP-inhibitors Maintenance to Enhance Secondary Cytoreduction Results","A New Fast DWI-based Magnetic Resonance Protocol for Surveillance in Patients With a High Risk of Ovarian Cancer Recurrence During PARP-inhibitors Maintenance to Enhance Secondary Cytoreduction Results","FOFU","Inclusion Criteria:\n\n* Patients with BRCA wild-type, HRP, high-grade serous ovarian cancer\n* No residual tumour at first debulking surgery\n* More than 6 months since the last platinum-based therapy\n\nExclusion Criteria:\n\n* Patients who will not consent to participate in the study","FEMALE","18 Years",{"count":45,"type":46},220,"ESTIMATED","OBSERVATIONAL","In ovarian cancer (OC), complete surgical debulking and platinum-based chemotherapy are the standard treatment, now followed by maintenance therapy with PARP inhibitors or Bevacizumab. However, in advanced-stage ovarian cancer, recurrence is common, with a progression-free survival of about 16 months. Secondary cytoreductive surgery (SCS) at the time of recurrence prolongs the overall survival and gives the possibility to extend the use of PARP-i. SCS is possible only when recurrence has limited extension. However, in OC, there is no well-established and widely accepted scheme for surveillance during maintenance therapy; ESMO guidelines suggest physical examination for the follow-up and allow ultrasound, CT, PET-CT and MRI to confirm the recurrence and plan surgical treatment if appropriate.",[50,51],"Ovarian Cancer","Recurrent Ovarian Carcinoma","NOT_YET_RECRUITING","2024-08-02",{"date":55,"type":56},"2024-08-07","ACTUAL",{"date":58,"type":46},"2024-09-01",{"date":60,"type":46},"2027-08-31",{"name":5,"class":6},1]